All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

nitroprusside 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	4631	14402-89-2

Description:

Molecule

Description

Synonyms: sodium nitroprusside hydrate sodium nitroprusside nitroprussiat nitroprusside sodium nitroprusside sodium salt sodium nitroferricyanide sodium nitroprussiate sodium nitrosylpentacyanoferrate nitroprusside

Sodium nitroprusside interacts with oxyhemoglobin to produce methemoglobin, cyanide, and nitric oxide (NO). NO then reacts with guanylate cyclase in vascular smooth muscle to produce cGMP that reduces intracellular calcium concentrations resulting in relaxation of vascular smooth muscle and consequent dilatation of peripheral arteries and veins. Molecular weight: 261.92 Formula: C5FeN6Na2O CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Drug dosage:

Dose	Unit	Route
50	mg	P

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
May 10, 1974	FDA	ROCHE
Aug. 25, 2021	PMDA	MARUISHI PHARMACEUTICAL Co., Ltd

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Fear	53.11	40.68	16	712	10460	34945743
Injury	46.10	40.68	17	711	20670	34935533

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Fear	79.07	41.67	24	1192	21962	79721210
Renal failure	61.25	41.67	38	1178	200930	79542242
Anhedonia	61.06	41.67	18	1198	14880	79728292
Renal injury	58.79	41.67	18	1198	16909	79726263
Unevaluable event	57.31	41.67	24	1192	55561	79687611
Injury	52.71	41.67	25	1191	77471	79665701
Hypotension	51.85	41.67	47	1169	440270	79302902
Multiple organ dysfunction syndrome	47.71	41.67	27	1189	120219	79622953
Emotional distress	43.67	41.67	18	1198	39951	79703221

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	C02DD01	CARDIOVASCULAR SYSTEM ANTIHYPERTENSIVES ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON Nitroferricyanide derivatives
FDA PE	N0000009909	Vasodilation
MeSH PA	D000959	Antihypertensive Agents
MeSH PA	D002317	Cardiovascular Agents
MeSH PA	D007202	Indicators and Reagents
MeSH PA	D020030	Nitric Oxide Donors
MeSH PA	D014665	Vasodilator Agents
FDA EPC	N0000175940	Vasodilator

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Hypertensive disorder	indication	38341003	DOID:10763
Acute heart failure	indication	56675007
Malignant essential hypertension	indication	78975002	DOID:10823
Decompensated cardiac failure	indication	195111005
Hypertensive urgency	indication	443482000
Acute exacerbation of chronic congestive heart failure	indication	698296002
Controlled Hypotension	indication
Coarctation of aorta	contraindication	7305005
Chronic obstructive lung disease	contraindication	13645005	DOID:3083
Hypovolemia	contraindication	28560003
Acute cerebrovascular insufficiency	contraindication	29322000
Tobacco amblyopia	contraindication	30483005
Hypothyroidism	contraindication	40930008	DOID:1459
Acute nephropathy	contraindication	58574008
Leber's optic atrophy	contraindication	58610003	DOID:705
Benign intracranial hypertension	contraindication	68267002	DOID:11459
Disorder of brain	contraindication	81308009	DOID:936
Hyponatremia	contraindication	89627008
Cobalamin deficiency	contraindication	190634004
Disease of liver	contraindication	235856003	DOID:409
Anemia	contraindication	271737000	DOID:2355

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Soluble guanylate cyclase	Enzyme	O75343 P33402 Q02108 Q02153	GCYB2_HUMAN GCYA2_HUMAN GCYA3_HUMAN GCYB1_HUMAN	ACTIVATOR				CHEMBL	CHEMBL
Atrial natriuretic peptide receptor 1	Enzyme	P16066	ANPRA_HUMAN					WOMBAT-PK

External reference:

ID	Source
D00614	KEGG_DRUG
4017812	VUID
N0000178982	NUI
15078-28-1	SECONDARY_CAS_RN
13755-38-9	SECONDARY_CAS_RN
4017812	VANDF
CHEBI:7596	CHEBI
CHEMBL2097081	ChEMBL_ID
CHEMBL136478	ChEMBL_ID
DB00325	DRUGBANK_ID
169D1260KM	UNII
7476	RXNORM
1098	MMSL
5489	MMSL
NOCODE	MMSL
d00136	MMSL
000664	NDDF
372860000	SNOMEDCT_US
387139005	SNOMEDCT_US
8163008	SNOMEDCT_US
C0028193	UMLSCUI
D009599	MESH_DESCRIPTOR_UI
73415791	PUBCHEM_CID

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Nitropress	HUMAN PRESCRIPTION DRUG LABEL	1	0187-4302	INJECTION, SOLUTION, CONCENTRATE	50 mg	INTRAVENOUS	ANDA	19 sections
Sodium Nitroprusside	HUMAN PRESCRIPTION DRUG LABEL	1	14335-132	INJECTION, SOLUTION	0.20 mg	INTRAVENOUS	ANDA	17 sections
Sodium Nitroprusside	HUMAN PRESCRIPTION DRUG LABEL	1	14335-133	INJECTION, SOLUTION	0.20 mg	INTRAVENOUS	ANDA	17 sections
Sodium Nitroprusside	HUMAN PRESCRIPTION DRUG LABEL	1	14335-134	INJECTION, SOLUTION	0.50 mg	INTRAVENOUS	ANDA	17 sections
sodium nitroprusside	HUMAN PRESCRIPTION DRUG LABEL	1	14789-012	INJECTION	25 mg	INTRAVENOUS	ANDA	21 sections
sodium nitroprusside	HUMAN PRESCRIPTION DRUG LABEL	1	14789-012	INJECTION	25 mg	INTRAVENOUS	ANDA	21 sections
Sodium Nitroprusside	HUMAN PRESCRIPTION DRUG LABEL	1	17478-014	INJECTION, SOLUTION, CONCENTRATE	50 mg	INTRAVENOUS	ANDA	22 sections
SODIUM NITROPRUSSIDE	HUMAN PRESCRIPTION DRUG LABEL	1	25208-003	INJECTION, SOLUTION, CONCENTRATE	25 mg	INTRAVENOUS	ANDA	15 sections
SODIUM NITROPRUSSIDE	HUMAN PRESCRIPTION DRUG LABEL	1	25208-003	INJECTION, SOLUTION, CONCENTRATE	25 mg	INTRAVENOUS	ANDA	15 sections
SODIUM NITROPRUSSIDE	HUMAN PRESCRIPTION DRUG LABEL	1	42571-265	INJECTION	50 mg	INTRAVENOUS	ANDA	12 sections
Sodium Nitroprusside	HUMAN PRESCRIPTION DRUG LABEL	1	43598-587	INJECTION, SOLUTION	50 mg	INTRAVENOUS	ANDA	20 sections
NIPRIDE RTU	HUMAN PRESCRIPTION DRUG LABEL	1	51754-1006	INJECTION, SOLUTION	0.50 mg	INTRAVENOUS	NDA	17 sections
NIPRIDE RTU	HUMAN PRESCRIPTION DRUG LABEL	1	51754-1018	INJECTION, SOLUTION	0.20 mg	INTRAVENOUS	NDA	17 sections
NIPRIDE RTU	HUMAN PRESCRIPTION DRUG LABEL	1	51754-1029	INJECTION, SOLUTION	0.20 mg	INTRAVENOUS	NDA	17 sections
SODIUM NITROPRUSSIDE	Human Prescription Drug Label	1	55150-320	INJECTION	50 mg	INTRAVENOUS	ANDA	12 sections
Sodium Nitroprusside	Human Prescription Drug Label	1	65145-101	INJECTION	50 mg	INTRAVENOUS	ANDA	19 sections
Sodium nitroprusside	HUMAN PRESCRIPTION DRUG LABEL	1	67457-839	INJECTION, SOLUTION, CONCENTRATE	25 mg	INTRAVENOUS	ANDA	19 sections
Sodium nitroprusside	HUMAN PRESCRIPTION DRUG LABEL	1	67457-999	INJECTION, SOLUTION, CONCENTRATE	25 mg	INTRAVENOUS	ANDA	19 sections
SODIUM NITROPRUSSIDE	HUMAN PRESCRIPTION DRUG LABEL	1	69097-532	INJECTION, SOLUTION, CONCENTRATE	50 mg	INTRAVENOUS	ANDA	12 sections
Sodium Nitroprusside	HUMAN PRESCRIPTION DRUG LABEL	1	70069-261	INJECTION, SOLUTION, CONCENTRATE	25 mg	INTRAVENOUS	ANDA	17 sections
Sodium nitroprusside	HUMAN PRESCRIPTION DRUG LABEL	1	70121-1189	INJECTION	25 mg	INTRAVENOUS	ANDA	18 sections
Sodium nitroprusside	HUMAN PRESCRIPTION DRUG LABEL	1	70121-1189	INJECTION	25 mg	INTRAVENOUS	ANDA	18 sections
sodium nitroprusside	HUMAN PRESCRIPTION DRUG LABEL	1	70436-028	INJECTION, SOLUTION, CONCENTRATE	50 mg	INTRAVENOUS	ANDA	19 sections
Sodium Nitroprusside	HUMAN PRESCRIPTION DRUG LABEL	1	70700-126	INJECTION, SOLUTION, CONCENTRATE	50 mg	INTRAVENOUS	ANDA	13 sections
Sodium Nitroprusside	HUMAN PRESCRIPTION DRUG LABEL	1	71288-202	INJECTION, SOLUTION	50 mg	INTRAVENOUS	ANDA	22 sections
Sodium Nitroprusside	Human Prescription Drug Label	1	71839-120	INJECTION	50 mg	INTRAVENOUS	ANDA	19 sections
SODIUM NITROPRUSSIDE	HUMAN PRESCRIPTION DRUG LABEL	1	72485-105	INJECTION	50 mg	INTRAVENOUS	ANDA	12 sections
SODIUM NITROPRUSSIDE	HUMAN PRESCRIPTION DRUG LABEL	1	72485-105	INJECTION	50 mg	INTRAVENOUS	ANDA	12 sections
SODIUM NITROPRUSSIDE	HUMAN PRESCRIPTION DRUG LABEL	1	72485-305	INJECTION	50 mg	INTRAVENOUS	ANDA	13 sections
SODIUM NITROPRUSSIDE	HUMAN PRESCRIPTION DRUG LABEL	1	72485-305	INJECTION	50 mg	INTRAVENOUS	ANDA	13 sections